Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College Hospital, London

Climacteric. 1998 Mar;1(1):12-7. doi: 10.3109/13697139809080676.

Authors

J C Stevenson¹, U Gaspard, B Avouac, C Bricaire, L Cardozo, P Collins, J P Devogelaer, M Dören, C Gennari, J M Kaufman, F Kuttenn, J D Ringe, C Scarafiotti, L Vanhaelst, L Zichella, R Ziegler, J Y Reginster

Affiliation

¹ Department of Urogynaecology, King's College Hospital, London.

PMID: 11913406
DOI: 10.3109/13697139809080676

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Coronary Disease / prevention & control
Estrogen Replacement Therapy*
Estrogens / administration & dosage
Estrogens / therapeutic use*
Female
Genital Diseases, Female / prevention & control
Humans
Quality of Life
Selective Estrogen Receptor Modulators / administration & dosage
Selective Estrogen Receptor Modulators / therapeutic use*
Urologic Diseases / prevention & control

Substances

Estrogens
Selective Estrogen Receptor Modulators